AOA Dx’s Multi-Omic Blood Test Shows Breakthrough Accuracy in Ovarian Cancer
Ovarian cancer remains one of the most lethal cancers among women, in large part because diagnosis often comes too late. Our portfolio company AOA Dx has reached an important milestone with the peer-reviewed validation of its multi-omic, AI-powered blood test for ovarian cancer detection.
The study, published in Cancer Research Communications (AACR) and conducted with the University of Colorado Anschutz Medical Campus’s Ovarian Cancer Innovations Group (OCIG) and the University of Manchester, analyzed more than 950 real-world samples. Results showed that AOA Dx’s test outperforms traditional biomarkers, detecting ovarian cancer with high accuracy across all stages, including early-stage disease, where current tools too often fall short.